Skip to content
value.today

Graviton BioScience Corp

🇺🇸 New York, New York, USABiotechnologyFounded 2020
Total raised
$98 M
5 rounds on record
Latest round
$5 M
Oct 2026
First round on record
Feb 2021
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Graviton BioScience Corp
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$5 MNo. 5$2 to $10 million

Graviton BioScience Corp: Raise no. 5, Oct 2026

Investors in this round

2 investors had bought by the notice of Nov 16, 2026: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $75 M offered; $70 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Rui Wu · Executive Officer
  • Samuel D Waksal · Executive Officer, Director, Promoter
  • David MacMillan · Director
  • Dixon Boardman · Director
  • James Boylan · Director
  • Michael Baran · Director
  • Ran Nussbaum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Samuel D. Waksal, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 16, 2026. Read the notice at the SEC.

equitySEC
Jan 2024$25 MNo. 4$10 to $50 million

Graviton BioScience Corp: Raise no. 4, Jan 2024

Investors in this round

1 investor had bought by the notice of Feb 14, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Samuel D Waksal · Executive Officer, Director, Promoter
  • Bihua Chen · Director
  • David D MacMillan · Director
  • James D Boylan · Director
  • Jeremy D Levin · Director
  • Ran D Nussbaum · Director
  • Stelios D Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Samuel D. Waksal, Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 14, 2024. Read the notice at the SEC.

equitySEC
Nov 2023$25 MNo. 3$10 to $50 million

Graviton BioScience Corp: Raise no. 3, Nov 2023

Investors in this round

1 investor had bought by the notice of Dec 4, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Samuel D. Waksal · Executive Officer, Director
  • Bihua D. Chen · Director
  • David D. MacMillan · Director
  • James D. Boylan · Director
  • Jeremy D. Levin · Director
  • Ran D. Nussbaum · Director
  • Stelios D. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Samuel D. Waksal, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 4, 2023. Read the notice at the SEC.

equitySEC
Dec 2022$40 MNo. 2$10 to $50 million

Graviton BioScience Corp: Raise no. 2, Dec 2022

Investors in this round

11 investors had bought by the notice of Dec 4, 2023: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$40 M of $50 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Samuel D. Waksal · Executive Officer, Director
  • Bihua D. Chen · Director
  • David D. MacMillan · Director
  • James D. Boylan · Director
  • Jeremy D. Levin · Director
  • Ran D. Nussbaum · Director
  • Stelios D. Papadopoulos · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Samuel D. Waksal, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 4, 2023. Read the notice at the SEC.

equitySEC
Feb 2021$4 MNo. 1$2 to $10 million

Graviton BioScience Corp: Raise no. 1, Feb 2021

Investors in this round

3 investors had bought by the notice of Feb 19, 2021: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $30 M offered; $27 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Steven Gordon · Executive Officer, Director
  • Philip Barach · Director
  • Richard Giroux · Director
  • Samuel Waksal · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Steven Gordon, Secretary. Source: SEC Form D, newest notice filed Feb 19, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Graviton BioScience Corp chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2026

That is all the official record says: Graviton BioScience Corp has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Graviton BioScience Corp is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Graviton BioScience Corp
NameRoleNamed in
Rui WuExecutive officerNov 2026
Samuel D WaksalExecutive officerNov 2026
Samuel D. WaksalExecutive officerDec 2023
Steven GordonExecutive officerFeb 2021
David MacMillanDirectorNov 2026
Dixon BoardmanDirectorNov 2026
James BoylanDirectorNov 2026
Michael BaranDirectorNov 2026
Ran NussbaumDirectorNov 2026
Samuel D WaksalDirectorNov 2026
Bihua ChenDirectorFeb 2024
David D MacMillanDirectorFeb 2024
James D BoylanDirectorFeb 2024
Jeremy D LevinDirectorFeb 2024
Ran D NussbaumDirectorFeb 2024
Stelios D PapadopoulosDirectorFeb 2024
Bihua D. ChenDirectorDec 2023
David D. MacMillanDirectorDec 2023
James D. BoylanDirectorDec 2023
Jeremy D. LevinDirectorDec 2023
Ran D. NussbaumDirectorDec 2023
Samuel D. WaksalDirectorDec 2023
Stelios D. PapadopoulosDirectorDec 2023
Philip BarachDirectorFeb 2021
Richard GirouxDirectorFeb 2021
Samuel WaksalDirectorFeb 2021
Steven GordonDirectorFeb 2021
Samuel D WaksalPromoterNov 2026